Takaharu Hirayama

USPTO Granted Patents = 15 (Patent Applications = 1)

EPO Patents = 5 (Patent Applications = 8)

Average Co-Inventor Count = 6.9

ph-index = 2

Forward Citations = 13(Granted Patents)

Location History:

Tsukuba, JP (2011)
Ibaraki, JP (2011 - 2012)
Fujisawa, JP (2017 - 2024)
Kanagawa, JP (2018 - 2024)

Company Filing History:

14 out of 1,179

Takeda Pharmaceutical Company Limited

patents

1 out of 850

Millennium Pharmaceuticals Limited

where one patent can have more than one assignee

Years Active: 2011-2025

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12435063 - Nitrogen containing heterocycles as CDK12 inhibitors (2025-10-07),

2. 12152027 - Heterocyclic compound (2024-11-26),

3. 11952344 - Heterocyclic compound and use thereof (2024-04-09),

4. 11897879 - Heterocyclic compound (2024-02-13),

5. 11584737 - Heterocyclic compound (2023-02-21),

6. 11495331 - Document creation assistance server and document creation assistance method (2022-11-08),

7. 11230545 - Heterocyclic compound (2022-01-25),

8. 10800754 - Heterocyclic amide compound (2020-10-13),

9. 10774083 - Heterocyclic amide compound (2020-09-15),

10. 10144742 - Quinoxaline compounds and uses thereof (2018-12-04),

11. 9957251 - Heterocyclic compound (2018-05-01),

12. 9745325 - Fused heterocyclic compound (2017-08-29),

13. 8273741 - Imidazo-pyridazinyl compounds and uses thereof (2012-09-25),

14. 8044049 - Fused heterocyclic derivative and use thereof (2011-10-25),

15. 8034812 - Imidazopyridazine derivative having kinase inhibitory activity and pharmaceutical agent thereof (2011-10-11),

Title: The Innovative Mind of Takaharu Hirayama

Introduction: Takaharu Hirayama, a distinguished inventor based in Kanagawa, Japan, has made significant contributions to the field of pharmaceuticals through his remarkable innovations. With a portfolio boasting 14 patents, his work primarily focuses on developing compounds that address critical health issues.

Latest Patents: Among his most recent patents are groundbreaking heterocyclic compounds. One patent involves a compound effective in inhibiting MALT1, which shows promise as a prophylactic or therapeutic drug for cancer and related conditions. The second patent presents another heterocyclic compound that acts as an antagonist on an NMD A receptor containing the NR2B subunit. This compound is anticipated to be beneficial in treating depression, bipolar disorder, migraine, pain, and peripheral symptoms of dementia, showcasing Hirayama's commitment to addressing various mental health issues.

Career Highlights: Takaharu Hirayama has held key positions at prominent organizations, including Takeda Pharmaceutical Company Limited and Millennium Pharmaceuticals Limited. His tenure at these companies has allowed him to leverage his expertise in drug discovery and development, leading to his impressive patent record.

Collaborations: Throughout his career, Hirayama has collaborated with notable colleagues, including Shinichi Imamura and Masanori Okaniwa. These partnerships have undoubtedly fostered innovation and contributed to the advancement of pharmaceutical research.

Conclusion: Takaharu Hirayama stands as a beacon of innovation in the pharmaceutical industry. With his extensive patent portfolio and dedication to developing impactful therapeutic drugs, he continues to influence the landscape of medical research. His work not only reflects his personal commitment to innovation but also offers hope for advancements in treating critical health challenges.

This text is generated by artificial intelligence and may not be accurate.